Perioperative sanitation of women with nonspecific vulvovaginitis and bacterial vaginosis

Elective operative care in gynecological practice deserves no less attention than emergency interventions. Potential risks of postoperative pyoseptic complications can be reduced by the prophylactic sanitation of the vaginal tract.

Objective: To evaluate the efficiency of preoperative sanitation of the vaginal tract with the combined drug Targifort in female patients with different forms of a gynecological disease who were elected to receive operative treatment.

Materials and methods: A clinical and laboratory examination and preoperative preparation of the vaginal tract were made in 96 patients aged 28 to 62 years with a number of gynecological diseases who were assumed to receive surgical treatment. During their preoperative preparation, the women were diagnosed with nonspecific vaginitis and vulvovaginitides of various etiologies. For prophylaxis, prior to surgery and to reduce postoperative complications, all the patients underwent local sanitation with the combined drug Targifort (metronidazole 500 mg, chloramphenicol 200 mg, natamycin 150 mg, hydrocortisone acetate 15 mg) as one suppository overnight for 10 days. The standard routine diagnosis spectrum was used. During the therapy, changes in clinical manifestations were assessed before surgical treatment and in the postoperative period.

Results: The decreased volume of vaginal discharge was found in 92.4% of the patients. Complaints of itching, burning, and discomfort in the vulvar area were noted to disappear in 78.2 and 66.4% of the women. “Amine” odor was gone in the all women receiving the therapy. The vaginal microflora spectrum was assessed immediately after therapy (before surgical treatment) and at 3–4 weeks after surgery. Normocenosis was obtained in 91.4% of the patients. This condition was retained in 88.2% of the women following surgery. The spectrum of the opportunistic vaginal flora was diverse prior to therapy. After vaginal sanitation, there was a reduction in the obligate anaerobic, facultative anaerobic flora, and fungal one. факультативно-анаэробной флоры и грибковой флоры.

Conclusion: Targifort confirmed its clinical efficacy and therapeutic safety and it can be recommended for the therapy of mixed vaginitis, vulvovaginal candidiasis and bacterial vaginosis in the perioperative period to prevent postoperative complications.